Oncology

The Institute for Value-Based Medicine travels to New York City to learn how technology and trust are key to making the leap to two-sided risk.

The outpatient community oncology setting is consistently less costly for cancer treatment as opposed to the outpatient hospital setting.

Our study provides the first evidence on site-specific Medicare spending on chemotherapy adjusting for patient comorbid illnesses, cancer type, and other cancer-related risks.

A once-weekly dose of carfilzomib (Kyprolis) in combination with dexamethasone has been approved to treat patients with relapsed or refractory (R/R) multiple myeloma. The approved regimen improved progression-free survival and had a better overall response rate than a twice-weekly regimen.

Employers may not look forward to purchasing healthcare, but they are in the position to transform the market. More employers are getting more involved in healthcare by championing alternative payment models and other services to their employees.

A new study has found that people living with HIV are at an increased risk of both first and second primary cancer incidence.

A test that uses next-generation sequencing (NGS) has been approved to detect and monitor minimal residual disease in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL).

Here are the top 5 articles for the month of September.

Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.

Earlier this week, 3 studies were released that investigated the financial difficulties seen in patients living with cancer. Such difficulties are referred to as “financial toxicity,” which was studied in patients with metastatic breast cancer and older patients, as well as the conversations about cost of care that women with breast cancer have with their physicians.

Earlier this week, drug manufacturer Astrazeneca announced the results from a phase 3 trial studying durvalumab (Imfinzi) among patients with stage III unresectable non­–small cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy.